X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.globenewswire.com/news-release/2023/07/17/2705624/0/en/Clearside-Biomedical-Announces-Enrollment-of-Multiple-Participants-in-its-ODYSSEY-Phase-2b-Clinical-Trial-of-CLS-AX-axitinib-injectable-suspension-in-Wet-AMD.html
https://www.onclive.com/view/china-s-nmpa-accepts-snda-for-frontline-toripalimab-plus-axitinib-in-metastatic-rcc
https://www.globenewswire.com/news-release/2023/06/01/2680184/0/en/Clearside-Biomedical-Opens-Enrollment-in-ODYSSEY-Phase-2b-Clinical-Trial-of-CLS-AX-axitinib-injectable-suspension-in-Wet-AMD.html
https://www.globenewswire.com/news-release/2023/04/18/2648825/0/en/Clearside-Biomedical-Announces-Plans-for-ODYSSEY-Phase-2b-Clinical-Trial-of-CLS-AX-axitinib-injectable-suspension-in-Wet-AMD.html
https://www.globenewswire.com/news-release/2023/02/02/2600340/0/en/Clearside-Biomedical-Announces-Positive-6-Month-Results-from-OASIS-Extension-Study-with-Suprachoroidal-CLS-AX-axitinib-injectable-suspension-in-Wet-AMD.html
https://www.clinicaltrialsarena.com/news/clearside-wet-amd-trial/
https://www.globenewswire.com/news-release/2022/07/26/2485749/0/en/Clearside-Biomedical-Completes-Dosing-in-OASIS-Phase-1-2a-Clinical-Trial-of-CLS-AX-axitinib-injectable-suspension-in-Wet-AMD-Patients.html
https://www.globenewswire.com/news-release/2021/12/21/2355973/0/en/Clearside-Biomedical-Announces-Positive-Safety-Results-from-OASIS-Phase-1-2a-Clinical-Trial-of-CLS-AX-axitinib-injectable-suspension-for-the-Treatment-of-Wet-AMD.html
https://www.globenewswire.com/fr/news-release/2021/03/02/2185135/0/en/Clearside-Biomedical-Announces-Completion-of-Patient-Dosing-in-First-Cohort-of-Phase-1-2a-Clinical-Trial-of-CLS-AX-axitinib-injectable-suspension-for-the-Treatment-of-Wet-AMD.html
https://www.globenewswire.com/news-release/2021/02/16/2175980/0/en/Clearside-Biomedical-Announces-CLS-AX-axitinib-injectable-suspension-Presentation-Delivered-at-Angiogenesis-Exudation-and-Degeneration-2021-Program.html
https://www.biospace.com/article/releases/clearside-biomedical-announces-first-patients-enrolled-in-phase-1-2a-clinical-trial-of-cls-ax-axitinib-injectable-suspension-for-the-treatment-of-wet-amd/
https://www.prnewswire.com/news-releases/nccn-announces-research-projects-exploring-axitinib-in-various-cancers-in-collaboration-with-pfizer-301192209.html#:~:text=All%20Products-,NCCN%20Announces%20Research%20Projects%20Exploring%20Axitinib%20in%20Various%20Cancers%2C%20in,and%20hepatocellular%20carcinoma%20(HCC).
https://www.indiainfoline.com/article/news-sector-pharma-healthcare/glenmark-pharma-receives-anda-tentative-approval-for-axitinib-tablets-1-mg-and-5-mg-120120100102_1.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-pharma-gets-tentative-nod-from-usfda-for-cancer-treatment-drug/articleshow/79505348.cms
https://www.nice.org.uk/guidance/ta645/resources/avelumab-with-axitinib-for-untreated-advanced-renal-cell-carcinoma-pdf-11452055183557#:~:text=Avelumab%20(Bavencio)%20with%20axitinib%20(,address%20uncertainties%20about%20the%20treatment.
http://www.pharmatimes.com/news/kidney_cancer_charity_slams_nice_rejection_of_keytrudainlyta_1347424
https://www.globenewswire.com/news-release/2020/08/10/2075922/0/en/Clearside-Biomedical-Announces-U-S-FDA-Acceptance-of-Investigational-New-Drug-Application-for-CLS-AX-axitinib-injectable-suspension-Administered-in-Suprachoroidal-Space.html
http://www.pharmatimes.com/news/merck,_pfizer_terminate_bavencio_head_and_neck_cancer_trial_1329296
https://www.prnewswire.com/news-releases/genome--company-announces-a-clinical-trial-collaboration-and-supply-agreement-with-merck-kgaa-darmstadt-germany-and-pfizer-300985435.html
http://www.pharmatimes.com/news/keytruda_combo_bags_eu_approval_in_rcc_1300883
http://www.pharmatimes.com/news/mhra_gives_bavencio,_inlyta_combo_early_access_to_medicines_status_1295006
http://www.pharmatimes.com/news/fda_approval_for_bavencio_combo_in_advanced_rcc_1288053
https://www.pmlive.com/pharma_news/merck_claims_key_fda_okay_for_bavencio_in_kidney_cancer_1288080
https://www.prnewswire.com/news-releases/fda-approves-bavencio-avelumab-plus-inlyta-axitinib-combination-for-patients-with-advanced-renal-cell-carcinoma-300850348.html
https://www.businesswire.com/news/home/20190430005302/en/Merck-Announces-First-Quarter-2019-Financial-Results/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
https://www.fiercepharma.com/pharma/merck-s-keytruda-stumbles-again-stomach-cancer-time-among-new-patients
https://www.reuters.com/article/us-merck-co-fda/mercks-keytruda-wins-fda-approval-as-combination-therapy-for-kidney-cancer-idUSKCN1RY0Q3
https://www.businesswire.com/news/home/20190422005185/en/FDA-Approves-Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Combination-Inlyta%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.fiercepharma.com/pharma/merck-heaps-early-pressure-bristol-s-opdivo-keytruda-s-kidney-cancer-debut
https://www.fiercepharma.com/marketing/between-merck-and-pfizer-race-kidney-cancer-but-analysts-are-calling-it-early
https://www.biospace.com/article/releases/fda-grants-priority-review-to-merck-s-supplemental-biologics-license-application-for-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-advanced-renal-cell-carcinoma/
http://www.pharmatimes.com/news/bavencio_combo_gets_fda_priority_review_for_kidney_cancer_1278091
https://en.prnasia.com/releases/apac/fda-accepts-sbla-and-grants-priority-review-for-bavencio-avelumab-plus-inlyta-axitinib-for-the-treatment-of-advanced-renal-cell-carcinoma-236866.shtml
https://www.reuters.com/article/us-merck-co-keytruda/merck-pfizer-combo-treatment-boosts-kidney-cancer-survival-idUSKCN1Q1037
https://www.fiercepharma.com/pharma/roche-yanks-tecentriq-kidney-cancer-apps-as-merck-pfizer-speed-toward-approvals
https://www.fiercepharma.com/pharma/pfizer-merck-kgaa-s-bavencio-flunks-another-trial-time-ovarian-cancer
https://endpts.com/merck-previews-an-early-hit-with-keytruda-combo-for-kidney-cancer-putting-more-pressure-on-rival-bristol-myers/
https://www.fiercepharma.com/pharma-asia/big-pharma-s-cancer-drugs-take-50-plus-discount-for-china-s-insurance-scheme
https://seekingalpha.com/article/4206092-daily-scoop-foamix-zooms-pfizer-merck-report-positive
https://www.reuters.com/article/us-merck-kidney-cancer/merck-kgaa-pfizers-immuno-drug-shown-to-alleviate-kidney-cancer-idUSKCN1LR1IY
https://www.biocentury.com/bc-extra/politics-policy/2018-08-17/china-unveils-cancer-drugs-medical-insurance-access-negotiation
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210234
http://www.x4pharma.com/news/x4-pharmaceuticals-reports-positive-clinical-data-from-phase-2-expansion-study-of-x4p-001-io-and-axitinib-in-patients-with-clear-cell-renal-cell-carcinoma/
https://www.pharmacompass.com/pdf/news/inlyta-axitinib-tablets-pfizer-v-apotex-1527500702.pdf
http://www.x4pharma.com/news/x4-pharmaceuticals-to-present-clinical-data-from-phase-2-expansion-study-of-combination-of-x4p-001-io-and-inlyta-axitinib-in-patients-with-clear-cell-renal-cell-carcinoma/
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-inlyta-axitinib-tablets-1524032482.pdf
https://www.fiercepharma.com/pharma/pfizer-s-inlyta-comes-up-short-recurrent-renal-cell-carcinoma-investigators-stop-trial
Market Place
Share 
